JMP Securities Reiterates Market Outperform on Sutro Biopharma, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has reiterated a Market Outperform rating for Sutro Biopharma (NASDAQ:STRO) and maintained a price target of $17.
September 16, 2024 | 2:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating for Sutro Biopharma, maintaining a $17 price target. This suggests confidence in the company's future performance.
The reiteration of a Market Outperform rating and maintenance of a $17 price target by JMP Securities indicates a positive outlook on Sutro Biopharma's stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100